Overview
CGON market data
Price History
CGON price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.08 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.21 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -3,602.7% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $24.10 – $79.39 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $6.8B · P/B 4.45 · P/S 1,089.64.
Company News
RBC Capital Maintains Outperform on CG Oncology, Lowers Price Target to $79Benzinga · Aug 7, 2026, 6:38 PM
Piper Sandler Maintains Overweight on CG Oncology, Raises Price Target to $85Benzinga · Aug 7, 2026, 4:55 PM
Truist Securities Maintains Buy on CG Oncology, Raises Price Target to $85Benzinga · Aug 7, 2026, 1:12 PM
CG Oncology Q2 EPS $(0.90) Misses $(0.67) Estimate, Sales $1.157M Beat $360.417K EstimateBenzinga · Aug 6, 2026, 12:53 PM
8-K filing — CG Oncology, Inc. (CGON)SEC EDGAR · Aug 6, 2026, 12:30 PM
Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law FirmGlobenewswire Inc · Jul 30, 2026, 11:00 AM
Reported Earlier, CG Oncology's Phase 3 BOND-003 Cohort C Data Published In The Lancet Oncology, Showing 75.5% Complete Response Rate In BCG-Unresponsive Bladder CancerBenzinga · Jul 28, 2026, 7:38 AM
CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet OncologyGlobenewswire Inc · Jul 27, 2026, 11:15 PM
ANI Pharmaceuticals Plans To Appeal Judge Sheldon K. Rennie's Decision To Deny ANI's Post-Trial Motions For New Trial, Judgement; Co. Seeks To Recover Assets' Value Sold to CG Oncology Under 2010 DealBenzinga · Jul 16, 2026, 8:38 PM
Wolfe Research Initiates Coverage On CG Oncology with Peer Perform RatingBenzinga · May 19, 2026, 12:15 PM